Aggressive Systemic Mastocytosis
Also known as: Aggressive Systemic Mastocytosis (ASM) / Aggressive systemic mastocytosis (disorder) / Aggressive systemic mastocytosis (morphologic abnormality) / Aggressive lymphadenopathic mastocytosis with eosinophilia (disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB15233 | Avapritinib | A selective tyrosine kinase inhibitor being investigated for the treatment of multidrug resistant gastrointestinal tumors. |
| DB00619 | Imatinib | A tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors. |
| DB06595 | Midostaurin | An antineoplastic agent used to treat high-risk acute myeloid leukemia (AML) with specific mutations, aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia (MCL). |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB15233 | Avapritinib | 1 | Completed | 1 |
| DB15233 | Avapritinib | 2 | Active Not Recruiting | 1 |
| DB18041 | Bezuclastinib | 2 | Recruiting | 1 |
| DB08870 | Brentuximab vedotin | 2 | Completed | 1 |
| DB09053 | Ibrutinib | 2 | Terminated | 1 |
| DB06595 | Midostaurin | 2 | Completed | 1 |
| DB06595 | Midostaurin | Not Available | Available | 1 |